Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
An objective and fair evaluation for risk/reward RE:BPX-501 / $BLCM
blog by Timothy Sullivan
https://medium.com/@tsullivan70/bpx-501-value-proposition-explained-d54aab57b58#.2rurbx7z0
You can say that again lol
Your ax to grind with 6pack over that bitter taste in your mouth beverage ticker now getting it's 2nd R/S in under a year, paints the obvious picture what your motive in here is today .. in fact I remember your feuding with him last year when you came in here and said the exact same BS on a drive by
Let's see since then yours might as well keep the trailing 'D' permanently and your sh*t didn't stick to the wall over here
That you defend that steaming pile=ZERO CREDIBILITY
Why don't you just take heed and get on the right side of the circumstance you are swimming upstream on both accounts
A/S has plenty of head room here
But more notable CRAZY LOW M/C in relation to LARGE REVENUES + ASSETS + IP
$HPTG LONG
TBARF I'm busting out of my skin to get short it's as sure as this play is LONG
Good luck but keep in mind you make your own!
Getting lots of coverage I really liked this piece very detailed and includes the background of the Head Honcho's http://investingnews.com/company-profiles/delmar-pharmaceuticals-cancer-gbm-treatment/
The more I watch L2 the past couple of days I am thinking there is more than shorting going on ... although I see the double prints going again today to support that theory
But in addition to shorts somebody (or several) with a large position is working on averaging down imo
Could possibly see teens unless the company can stem this tide with some kind of substantial news .... in part the price direction here will depend on the broader markets which are currently aiding the cause to walk this down
Plus the chart looks like crap death cross on the moving averages may also take a toll on pps
Setting some GTC's in the teens today in case we dip again like it did Feb 2 intraday low was .185
Not sure if this is breaking news or if I am just finding out
ASCO has named Cancer Immunotherapy the Advance of the Year 2016!
[url]www.cancerprogress.net/cca/clinical-cancer-advances-2016#.Vs0u_txNjx4.linkedin
[/url][tag]CancerProgress.Net[/tag]
Good space to be in right now and add the increased government funding this year to fast track the cause ....patience here will prevail LARGE
LOL Good to see you here & hope you are well. Hopefully we will get some color on that point in the
10K due March 31 hehe
Just a thought but perhaps they will license the cold weather battery tech to other vehicle manufacturers? In all likelihood the potential for expansive revenue would exceed that than if they kept it in house just for themselves.
In fact I have always been of the view this company aspires to build a 'better mousetrap' in several of their endeavors/patents/IP and then share it with the world (in exchange for royalties);) ..I could be wrong and it is pure speculation on my part.
There is and has been for years electric defrost apparatus on our rear windows here in Canada maybe a similar technology embedded in the glass combined with electric heat & a blower fan ... I am no engineer but I don't think it is out of reach or much of an obstacle
I did send them an email tonight and included that among some other questions. I will report back if and when I get an answer for you.
You sound a tad on the grumpy side Mr.NightOwl perhaps you should call it a night a little earlier?? ... now to address in parts your little rant.
1)This is certainly no pump & dump more on that in point #2 but there has certainly been a significant short interest in this ticker. I used to see the double prints on the tape a lot not so long ago ... which is a tell tale sign ...not so much lately I think they mostly covered on the last dip and red markets everywhere for weeks gave them an enormous assist on this under the radar ticker ...it's been a shorter's field day EVERYWHERE not one stock immune ... that in no way correlates with your 'pump & dump' theory nor has there been any 'pump'
Please do explain how it has been 'pumped??...if I did miss something.
Short Selling Data
Short Interest 5,000 (489.62%)
Jan 29, 2016
http://www.otcmarkets.com/stock/LEOM/profile
I think LEOM is picked on a lot by shorts because it has low relative volume and thus easy to manipulate the large sized spreads given the low, tightly held float.
But hey that provides for some WONDERFUL volatility so that we all may use this financial instrument to...well let me use your own words
As a relatively new start up (2012) I imagine there were front end costs like any business in the first 3 years ... typical for the bulk of cash flows rolled into asset acquisition and other one time expenses getting established. Bear in mind the net $660K was 2014
Should make for juicier profit margins imo for 2015 and our timing for this merge is impeccable when you consider this standpoint we hit the ground running with growing pains behind us
http://perleinyc.com/prostar/
My mistake we are not going to see a Q this week next up is the 10K so may have to wait until the end of March to see that ..it's OK it's not like anybody reads this board ... RSI @ 53.12 nice day today here
2 Poster Abstracts presenting @ BMT Tandem Meetings in Honolulu Sun Feb 21
BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) Treatment Following TCR Alpha Beta Depleted Stem Cell Transplantation in Adults and Children with Hematological Disorders
Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children with Thalassemia Major (TM) Given Alfa/Beta T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (HSCT)
For your reading pleasure, as the only one on this board who can completely understand and decipher ;) I just found this paper published on the 17th seems to correlate directly to the $ENUM thesis
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Rising RSI about to make a vertical cross on the 11 dma if the Q is good and the RSI sustains 50 and further up this could well make new 52 weeks highs pretty quickly here
I added .22's this week ...got a little shaky around here of late lol we are due
Pent up demand for this stock is revealing itself in steps as the pipeline unfolds ...with BP partner news we will be joining the big leagues...and imo organically I might add pps appreciation will nullify any notion of R/S with the tighter float a few were comparing to in last night's discussion
Sneaky large sized buys throughout yesterday ...very telling where we go from here
GOOOD Morning! PATENT ALLOWANCE PolyStart
Found this succinct summary of the company's current endeavors and pipeline posted on the Yahoo newsfeed ..good read for newbies
Del Mar Pharmaceuticals Inc. (OTCMKTS:DMPI)
DelMar is developing VAL-083. In DNA, sometimes we get what are called interstrand crosslinks, which connect the two strands in DNA and inhibit the standard DNA functions of replication and transcription. Crosslinks are very toxic to surrounding cells, and can quickly induce cell death. VAL-083 seeks to induce interstrand crosslinks in the DNA of cancerous cells, and in turn, induce apoptosis and the halting of cancerous cell replication. This type of crosslink induction is at the core of the majority of cancer therapies - primarily chemotherapy drugs - but DelMar's candidate is a different kind of agent that would allow it to be administered as a single therapy or in combination with some of the most commonly used therapies available - platinum based, or tyrosine kinase based treatments, for example.
The drug is already approved in an oncology indication in China, which sets it in great stead for a US or European approval, and to date we've seen some promising trial results. Mid stage data from an ongoing phase I/II in glioblastoma multiforme brain cancer demonstrated tolerability, low negative side effects, and an improved survival rate at 6, 9 and 12 months following treatment, building on earlier preclinical data that served as proof of concept. GBM is notoriously difficult to treat, and if approved, VAL-083 would be targeting a billion dollar market.
Full completion is expected at the beginning of December this year, and we should get top-line data shortly after. If we get tumor response that mimics mid stage data, the drug could move into a pivotal trial shortly after, and DelMar could be well on its way towards its first approval.
http://finance.yahoo.com/news/4-stocks-consider-biotech-turnaround-165500882.html
Got those for my dog shareholder #76
..or thereabouts
Holy smokes I didn't remember the volume being so low during that time LOL I do remember though that when BMAK back in the day would get out of the way or at least play fair and up tick it moved up with lightning fast speed
Prior to that run I found it battered down at .004 - .0075 ...but that was all with 0 revs this time we going much higher and eventually sustaining somewhere silver imo I wouldn't rule out landing between .10 - .20 before the end of this year and that's only considering what we already know as in the HERE and NOW ...what else is coming??
GONNA BE A HAPPY ANNIVERSARY!! WEEEEEE $HPTG
No one can say for sure how the market will react and how fast & hard the pps gains/pulls but this is a relatively low float and well known in the past for fast moves up when they happen attracting many daytraders/flippers...as all pennies do... it could get pretty volatile at that point... I see a multi-day/week run on the way here before any significant pullback but I highly doubt the market will take it all back like it did with those pre-rev bio's smart money will arrive on the bid for dips once the books are revealed
I know of one I am sure there were several
I was accumulating PeePeeCH from late Feb thru March 2015 .002 - .0045 by mid June the top was just under .15 intraday with plenty of opportunity in the .10 range ... of course I did not get all of that never do after 1000% sold 2/3 of my sub pennies before it hit .05 lol ...that one was highly speculative ...$HPTG is far more solid I don't see why that won't happen here this year and possibly more
Not as easy to find those as it was a few years ago but imo we are all but guaranteed a mirror run with $HPTG the difference being we should sustain the gains once the consolidation period occurs with the revs here
I am on free shares here been trading $HPTG since Nov '14 I now have this one in my long account as opposed to my flipping account where I started and as long as everything is on the UP and UP I intend to stay put beyond 2016
Oh another one to look at with an incredible 2 day run late June was
ARE-EX-EM-DEE I was not involved but eyeing entry there soon after giving it all back it has shown strength stair stepping up with solid accumulation
Good luck to all ... bearing in mind "You make your own luck"
Looks like we can view it live from their website 10 AM EST if not live, for sure afterwards ...
Portal to Webcast Mon Feb. 8th 10 AM EST
Broke the 200 dma I wonder how low we go ...will continue scooping on the bid if it continues lower ...although this week my GTC wasn't working for some reason I was passed over repeatedly with whacks going below it so I slapped .80 a few times
Incredible,informative website for Delmar for new investors...take a gander
Won't need either we are hitting the ground running with substantial and growing revs ... Share price will rise organically (no R/S) and they have lots of head room with the current A/S imo
$HPTG
That number is how many brokerages (under their "street name") currently hold shares for a multitude of clients ...there is no telling how many people this represents but I am certain it is more than 75
This goes for all tickers ...
ie: I use a margin account and I think most traders do as well.
And so with a margin account, technically, my broker owns my shares and I am the beneficiary. There are quite likely many others who own HPTG with the same broker I use, but we would all be counted as 1 of those 75 under the "street name" of our shared brokerage
The way I understand it is if you have a non-margin account the shares would then be issued under your own name.
I am pretty sure even with a margin account you can request the certificates to be issued in your own name ... some may choose to do this if they are a loooooong long ...and the only reason I know of to do this is that it would then prevent the brokers ability to lend out those shares for the purpose of shorting the stock.
Here is a further explanation
http://www.wikinvest.com/stock/Apple_(AAPL)/What_Difference_Between_Shareholder_Record_Beneficial_Owner_Shares
Here here King K for President! Nice push indeed
Been here a long while and there have always been great contributors...but certainly welcome all the recent stellar additions of late... what a breath of fresh air around here
Nice clean ibox fantastic group here congrats to all what stands out most atm is the CHART PORN!
Just took a boo at the weekly RSI 55.58 first time positive since March and very abrupt bullish indications since November
Weekly 50 DMA .0051 nice move above today this could get to a penny without news/fins this week imo solid company here more are seeing what is coming ..haven't added since .0035 but I think I just talked myself in to it lol
Weekly Chart
And here is the presentation ... just watching now
http://noble.mediasite.com/mediasite/Play/5355702bbd66458b989daa6759bc54071d?catalog=3a734bfc-b7b0-4496-95ea-5193c0db8116
I am liking this one more every minute and have been watching it trade very closely still want my 80's bids to fill but no dice and not likely
With a proven successful model, this company takes a multi year jump start and hits the ground running as a result of the benefit of years of clinical work already completed, ODD already in Europe & the US for malignant gliomas, approval in China for VAL-083 and more indications & developments in the pipeline this year ...loads of headroom with M/C only $38M
.. the fast track will be the up list on this one and looks to me like it will be a clean, easy & natural transition soon
So hard to decide where to add tomorrow I got more TeePee today in the high 40's, now between DMPI SNGX, or I always like more ENUM ...there's never enough cash to go around at times like this lol but all of those have had notable reduced selling past 2 sessions and indicators going positive here's hoping they're all cooking with gas from here
Pretty much mirrored my strategy here having bought .01's & .02's a year ago I bit the bullet & averaged down with trips and teens in Oct ...then got all my capital back on the pop in high 4's selling half... was remarkable... averaging down doesn't always work but the clues were here by then that something was coming and I rescued all my soldiers! ... have accumulated more in the .003's since
I don't think there is a better upside virtually assured on the OTC than $HPTG right now I think I want more
Yes I saw that a couple of days ago and as a matter of fact before it was even done I added my second tranche of shares here ;)
Getting quite a bit of coverage on the partnership with MD Anderson saw this released today seems to be a prestigious publisher for the pharm industry
http://drugdiscovery.pharmaceutical-business-review.com/news/delmar-md-anderson-partner-to-accelerate-development-of-val-083-anti-cancer-drug-140116-4784298
I have the net @ $123000 based on those numbers at a glance unless I missed something but either way pretty skookum margins for a "contractor" hey?
Also nice to see that besides being a third party provider they are pursuing & developing a network of stations owned by $JNSH
JNS Holdings Corporation Through Its Subsidiary JNS Power Continues to Expand EV Services
January 13, 2016 11:12 AM Eastern Standard Time
CHICAGO--(BUSINESS WIRE)--JNS Holdings (OTC: JNSH), through its wholly owned subsidiary JNS Power & Control Systems, Inc. one of the largest independent owner, operator, and provider of electric vehicle (EV) charging stations, commercial and residential sales, installations and consulting services in the Chicago area, announced today that it continues to grow its EV charging division.
Recent completed EV projects totaling $255,000 in revenue as follows:
Volta – (Electronic display unit) Installations:
Northbrook Court – Two level 2 charging stations
Oakbrook Center – Two level 2 charging stations
Northeastern Illinois University – Installations:
Campus Parking Structure – Two dual head level 2 charging stations
Woodfield Mall – Installations:
Two level 2 charging stations & one level 3 DC Fast charger
Other 3rd Party Maintenance & Service work
The above referenced work relates to our EV charging services only and does not include other projects.
The companies average industrial / commercial installation cost breakdown is as follows:
Level 2 EV charger installation - $5,000 to $10,000 (typical commercial installation could include directional boring, concrete work, saw cutting, foundation work, transformer & electrical distribution) Level 2 EV charger unit purchase - $6,500 (network capable commercial grade)
Level 3 DC Fast Charger installation - $35,000 to $50,000 (typical commercial installation could include directional boring, concrete work, saw cutting, foundation work, transformer & electrical distribution) Level 3 DC Fast Charger 50Kw unit purchase - $25,500 (network capable commercial grade)
Brian Howe President & CEO stated, “We are continuing to implement our business strategy to grow the EV Charging segment of our business through the development of our own, owner operated network as well as third party sales/service providers. EV charging is an extremely fast developing sector and we intend to be a leader in our marketplace, the Chicago metropolitan area, the third largest market in the country.”
About JNS Holdings Corporation:
JNS Holdings focuses on building solid growth for our investors and shareholders through expansion of our core businesses and subsidiaries, see (www.jnsholdings.com) while seeking additional strategic opportunities. JNS Power & Evolve USA Charging Corporation is the Chicago (IL) based subsidiaries of JNS Holdings specializing in EV infrastructure solutions. JNS is committed in creating a useful and well maintained network for EV charging. The corporate headquarters is located in Wheeling, Illinois. Connect with JNSH on Facebook or Twitter.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Contacts
JNS Holdings Corporation
Brian Howe – CEO
(847) 520-2899
www.jnsholdings.com
info@jnsholdings.com
http://www.businesswire.com/news/home/20160113005891/en/JNS-Holdings-Corporation-Subsidiary-JNS-Power-Continues
Did you miss $DMPI CEO Jeffrey Bacha's presentation at #BTS16?
Watch it here:
http://ir.delmarpharma.com/ir-calendar
Nice announcement during the presentation today
During a presentation on January 12, 2016, DelMar Pharmaceuticals, Inc. (the “Company”) disclosed that it will collaborate with the University of Texas MD Anderson Cancer Center on the development of the Company’s lead product candidate, VAL-083, for the treatment of brain cancer. As part of the collaboration, MD Anderson will initiate a new Phase II clinical study with VAL-083 in patients with glioblastoma multiforme (“GBM”), the most common and aggressive form of brain cancer, prior to bevacizumab (Avastin™) exposure. Patients eligible for the study will have recurrent GBM characterized by a high expression of MGMT, the DNA repair enzyme implicated in drug-resistance and poor patient outcomes following current front-line chemotherapy. MGMT promoter methylation status will be used as a validated biomarker for enrollment and tumors must exhibit an unmethylated MGMT promoter for patients to be eligible for the trial.
http://ih.advfn.com/p.php?pid=nmona&article=69975162
Presenting tomorrow @ Biotech Showcase 11 AM Pacific (I don't think they PR'd their participation)
http://www.ebdgroup.com/bts/presenters/prs_comps.php
Also found them on the list for the prestigious CEO & Investor Conference Feb 8-9 in New York
https://www.bio.org/events/conferences/2016-presenting-companies
I added here today
I see the Michael J Fox Foundation will also be represented there if you scroll all the way down to 'Patient Advocacy Groups' ...perhaps a platform for launching our next indication?
Isn't it insane how many to choose from oversold?? Sure hope everything swings just as wild back up ... coming in here this week sure wish I'd taken heed when you mentioned this one Oct ..besides your biotech acumen you seem to have developed a sixth sense for great picks! Certainly can expect increased awareness and coverage 2016 the past few weeks have gotten a bum rap here & everywhere
Gap has more than filled on this dip (didn't quite do so last dip first week Dec where my GTC bid was at that time and it got away on me again lol) very likely this pps will be close to as good as it gets
Hi RK Nice to hear from you I sure don't mind whoever walking this down helping fill my bids below .20 yesterday and today I was delighted .. deserved that I have slapped here as high as .30 ;)Looking forward to this sleeper waking up 2016
DelMar Pharmaceuticals, Inc. - "Modernizing Medicines: DelMar’s Strategic Edge for VAL-083 in Oncology"
NEW YORK, NY / ACCESSWIRE / January 8, 2016 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
In his new blog, DelMar CEO Jeffrey Bacha explains how the Company is developing its lead drug candidate, VAL-083, for glioblastoma multiforme (GBM) by combining published preclinical and clinical data and a modern understanding of biologic pathways. Mr. Bacha describes how VAL-083 attacks brain tumors differently than current therapies and presents a potential new treatment paradigm for the majority of GBM patients who are underserved by current treatments. Finally, he provides his outlook for DelMar in 2016 in which he states, "DelMar has an exciting year in store in 2016, as we continue to build on the momentum of encouraging data with VAL-083 from our ongoing Phase II trial in refractory GBM and newly planned clinical studies in front-line GBM and NSCLC." Read the full blog post from Mr. Bacha on TheChairmansBlog.com
TheChairmansBlog.com/
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
About TheChairmansBlog.com
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com
SOURCE: TheChairmansBlog.com
https://www.accesswire.com/435397/DelMar-Pharmaceuticals-Inc-Modernizing-Medicines-DelMars-Strategic-Edge-for-VAL-083-in-Oncology